These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35582947)

  • 21. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Kosiborod MN; Deanfield J; Pratley R; Borlaug BA; Butler J; Davies MJ; Emerson SS; Kahn SE; Kitzman DW; Lingvay I; Mahaffey KW; Petrie MC; Plutzky J; Rasmussen S; Rönnbäck C; Shah SJ; Verma S; Weeke PE; Lincoff AM;
    Lancet; 2024 Sep; 404(10456):949-961. PubMed ID: 39222642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
    Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
    Verma S; Al-Omran M; Leiter LA; Mazer CD; Rasmussen S; Saevereid HA; Sejersten Ripa M; Bonaca MP
    Diabetes Obes Metab; 2022 Jul; 24(7):1288-1299. PubMed ID: 35332654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.
    Yin DG; Ding LL; Zhou HR; Qiu M; Duan XY
    Endocr J; 2021 Jun; 68(6):739-742. PubMed ID: 34024887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
    Verma S; Fainberg U; Husain M; Rasmussen S; Rydén L; Ripa MS; Buse JB
    Diabetes Obes Metab; 2021 Jul; 23(7):1677-1680. PubMed ID: 33606902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
    Mosenzon O; Miller EM; Warren ML
    Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
    Wang J; Yang J; Jiang W; Liu W; Shen Z; Gao Z; Chang B
    Diabetes Obes Metab; 2024 Nov; 26(11):5157-5166. PubMed ID: 39188242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
    Verma S; Bain SC; Monk Fries T; Mazer CD; Nauck MA; Pratley RE; Rasmussen S; Saevereid HA; Zinman B; Buse JB
    Diabetes Obes Metab; 2019 Jul; 21(7):1745-1751. PubMed ID: 30851070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    Lincoff AM; Brown-Frandsen K; Colhoun HM; Deanfield J; Emerson SS; Esbjerg S; Hardt-Lindberg S; Hovingh GK; Kahn SE; Kushner RF; Lingvay I; Oral TK; Michelsen MM; Plutzky J; Tornøe CW; Ryan DH;
    N Engl J Med; 2023 Dec; 389(24):2221-2232. PubMed ID: 37952131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell SA
    Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
    Mosenzon O; Capehorn MS; De Remigis A; Rasmussen S; Weimers P; Rosenstock J
    Cardiovasc Diabetol; 2022 Sep; 21(1):172. PubMed ID: 36056351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
    McGuire DK; Busui RP; Deanfield J; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter N; Engelmann MDM; Hovingh GK; Ripa MS; Gislum M; Brown-Frandsen K; Buse JB
    Diabetes Obes Metab; 2023 Jul; 25(7):1932-1941. PubMed ID: 36945734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
    Leiter LA; Bain SC; Bhatt DL; Buse JB; Mazer CD; Pratley RE; Rasmussen S; Ripa MS; Vrazic H; Verma S
    Diabetes Obes Metab; 2020 Sep; 22(9):1690-1695. PubMed ID: 32372454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
    Jendle J; Birkenfeld AL; Polonsky WH; Silver R; Uusinarkaus K; Hansen T; Håkan-Bloch J; Tadayon S; Davies MJ
    Diabetes Obes Metab; 2019 Oct; 21(10):2315-2326. PubMed ID: 31215727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.